Agios Pharmaceuticals Inc (AGIO): Price to Sales

Corporate company logo of Agios Pharmaceuticals Inc (AGIO)

Agios Pharmaceuticals relies on a strong school of cell biology and minimal bureaucracy, as evidenced by its P/S trajectory. Currently, this parameter reaches 13.50. The company is implementing eco-friendly technical processes in biopharmaceuticals while adhering to ESG principles. High trust from investors and patients has solidified the brand's image as a stable innovator in the treatment of rare metabolic pathologies.

Agios Pharmaceuticals, Inc. - AGIO P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Agios Pharmaceuticals Inc (AGIO)

- current price and projected stock value:
Price Chart agios.com|AGIO - Price Target Chart
- stock exchange capitalization data:
Market Value Agios Pharmaceuticals Inc|AGIO - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Agios Pharmaceuticals|AGIO - Book Capitalization|Market Capitalization to Book Value agios.com|AGIO - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Agios Pharmaceuticals|AGIO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Agios Corp|AGIO - Company Aggregate Debts|Debts to Book Capitalization Agios Pharmaceuticals Inc|AGIO - Company Long-Term Debts|Short-Term Indebtedness Agios Pharmaceuticals|Interim Coverage Ratio agios.com
- financial results and valuation multiples details:
AGIO - Company Net Income|Expected Net Profit Agios Pharmaceuticals|AGIO - Price to Earnings Ratio|Market Cap to Projected Earnings Agios|AGIO - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Agios Pharmaceuticals Inc|AGIO - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Agios Pharmaceuticals|AGIO - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months agios.com|AGIO - Earnings growth in current year|Earnings growth forecast for next year Agios Pharmaceuticals
- issuer revenue and sales details:
AGIO - Company Revenue|Company Future Revenue agios.com|AGIO - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Agios Pharmaceuticals Inc
General company analysis:AGIO agios.com
Core merchandise of Agios Pharmaceuticals

Agios Pharmaceuticals (AGIO) is integrating robotic genetic screening and predictive metabolism analysis software, establishing a high-tech foundation for future revenue growth. This price-to-sales chart reflects the market value of each dollar of sales, allowing investors to determine the premium paid for the company's potential and avoid entering the asset at the peak of unjustified optimism.

Competing companies

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|P/S Multiple ETNB (89bio, Inc.)|P/S Multiple structuretx.com GPCR|MiMedx - P/S Multiple|Price-to-Revenue Multiple Rezolute Inc (RZLT)|LXRX: P/S Multiple|MBX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Altimmune, Inc.|Price to Sales aardvarktherapeutics.com AARD|Price-to-Revenue Ratio Sagimet Biosciences Inc. (SGMT)|Price-to-Revenue Coefficient BioAge Labs|Biomea - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QNCX|GUTS - Price-to-Revenue Ratio|Price-to-Sales Ratio VTVT|ATPC: P/S Multiple|Pluri - Market Capitalization-to-Revenue Ratio|SYBX (Synlogic Inc.) - P/S Multiple|P/S Multiple Lipocine Corporation|Price-to-Revenue Ratio Matinas BioPharma (MTNB)|SPRB (sprucebiosciences.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Galecto GLTO|CTCX - Market Cap to Revenue|Lumos Pharma Corp - P/S Multiple|ONVO - P/S Multiple|RDUS: P/S Multiple